THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
S U M M A R Y
DIARY: August 29, 2008 12:00 PM Friday;
Millie meeting at Kaiser review progress UCSF clinical trial treat IBC.
2...Agenda Integrated Work Plan Kaiser UCSF
3...Medical Chart Reports Examination Diagnosis Prescription Prognosis
Click here to comment!
Meeting Examination Kaiser Backup Doctor Review Strategy Work Plan 3
1303 - ..
1304 - Summary/Objective
130501 - Follow up ref SDS B0 0000. ref SDS 92 0000.
130510 - ..
1308 - Progress
130901 - Agenda Integrated Work Plan Kaiser UCSF
130903 - Follow up ref SDS B0 QY5I, ref SDS 92 QY5I.
130906 - **************************************************************
130908 - Wasn't enough time to create this record; at the end is the
130909 - doctor's medical chart that is correct. ref SDS 0 YT5N
130911 - ..
130912 - Kept this content as a template in case there is time later
130913 - to write up the record.
130915 - **************************************************************
CT Test 080212 Findings Support Diagnosis IBC Progression Disease 4t
B50401 - ..
B50402 - Medical Chart Reports Examination Diagnosis Prescription Prognosis
B50404 - Follow up ref SDS B0 YT5N, ref SDS 92 YT5N.
B50406 - Received the doctor's report in the medical chart for the meeting
B50407 - today...
B50409 - ..
B50410 - 1. Received: 8/29/08 1:04 PM
B50412 - ..
B50413 - 2. .... [patient] is a 72 Y female with a history of inflammatory
B50414 - cancer of left breast who was initially diagnosed 03/04/02.
B50415 - She had recurrent disease noted initially in the cervical LN's
B50416 - 03/03/04. On E2100 Study with Avastin, but she had a PE noted
B50417 - on CT 11/03/2004. Then, because of progression of disease, the
B50418 - patient was started on Taxotere and Xeloda 4/15/05. She had a
B50419 - total of 8 cycles ending 9/16/05. She had a palliative left
B50420 - mastectomy performed 10/21/05. Then her left chest lesions
B50421 - began expanding again. The patient started Taxotere and Xeloda
B50422 - again 07/21/06 for 7 cycles. She was started on a Clinical
B50423 - Trial 02/01/07 at UCSF and was randomized to the Erbitux only
B50424 - (no Carbo) Arm.
B50426 - ..
B50427 - She had weekly Carboplatin added 03/13/08 because of
B50428 - progression of disease. She has missed a total of 4 treatments
B50429 - because of neutropenia. Her CA 15-3 continues to increase
B50430 - (08/21/08 was 96).
B50432 - ..
B50433 - Medical chart aligns with case study patient history neutropenia in
B50434 - the record yesterday on 080828. ref SDS C5 8O7I
B50436 - ..
B50437 - Patient history on 080502, ref SDS 92 SU49, shows Millie responded to
B50438 - full dose Carboplatin 230 mb, prescribed in UCSF Chemotherapy Order on
B50439 - 080313. ref SDS 78 2N4N On 080423 Millie cited significant recovery
B50440 - from IBC with only 50% of treatments using full dose of Carboplatin.
B50441 - ref SDS 87 OY7S Another letter to UCSF on 080423 explained dramatic
B50442 - reduction of IBC rash getting full dose of Carboplatin. ref SDS 87
B50443 - TY7X Examination at UCSF on 080501 found substantial improvement
B50444 - recovering from IBC. ref SDS 91 NW3N On 080501 UCSF evidently reduced
B50445 - the dose of Carboplatin, which conflicted with patient's letter on
B50446 - 080423, and this was not discovered until 080605, because of delays
B50447 - submitting the Chemotherapy Order, as set out in the record on 080529.
B50448 - ref SDS A0 MM9I On 080502 examination by primary care physician at
B50449 - Kaiser finds favorable response to treatment, ref SDS 92 NH4N, despite
B50450 - getting only 50% of prescribed Carboplatin chemotherapy, ref SDS 92
B50451 - NH4N, which Millie has tolerated well shown by significantly increased
B50452 - exercise. ref SDS 92 ZD9O
B50454 - ..
B50455 - On 080528, Millie notified the medical team updating the record; since
B50456 - 080507 I have increased daily training with respect to distance and
B50457 - faster times. There have been no further episodes of elevated pulse.
B50458 - I am recovering well after climbing hills (e.g. pulse climbs to 140+
B50459 - or -, then quickly drops back to below 120), which seems like a good
B50460 - sign. ref SDS 98 IK5V
B50462 - [On 081012 Millie experienced significantly elevated pulse
B50463 - while hiking at Lafayette reservoir and over a prolonged
B50464 - period of 2 laps - 5.5 miles. On the 3rd lap pulse settled
B50465 - back to normal. ref SDS D0 4I8M
B50467 - ..
B50468 - CA 15-3 and IBC rash began to increase after dose of Carboplatin was
B50469 - reduced on 080501.
B50471 - ..
B50472 - Medical Chart continues...
B50474 - 3. Current Medications
B50476 - PROCHLORPERAZINE 10MG....... Compazine. 080313, ref SDS 74 FA4H
B50477 - ONDANSETRON 8 MG TABLETS.... Zofran.... 080313, ref SDS 74 FA4H
B50478 - CEPHALEXIN 500 MG CAPSULES.. Keflex.... 080409, ref SDS 85 F142
B50479 - FLUOXETINE 20 MG CAPSULES... Prozac.... 080305, ref SDS 73 5L5M
B50480 - NEUPOGEN 480MCG/1.6ML.................. 080502, ref SDS 92 NL4M ,
B50481 - WARFARIN 4 MG TABLETS....... Coumadin.. 061002, ref SDS 14 MI5I
B50482 - TIMOLOL MALEATE 0.5% EYE.... Eye drops
B50483 - ACYCLOVIR 800MG............. Zoviraxe.. 070614 (no record prescribed by Doctor Rugo to treat cold sore on lip)
B50484 - LORAZEPAM 1 MG.............. Ativan.... 070921, ref SDS 35 3N8J
B50485 - Cetuximab................... Erbitux... 070201, ref SDS 25 4N5M
B50486 - Carboplatin............................ 080313, ref SDS 78 2N4N
B50488 - ..
B50489 - The medical chart does not include contrast medium treatment for CT
B50490 - tests reported in Kaiser's list of medications received during the
B50491 - meeting on 080502. ref SDS 92 SY4M Continues omission from medical
B50492 - chart on 080627. ref SDS B0 4B5K Kaiser changed the contrast medium
B50493 - to...
B50495 - Barrium Sulfate Suspension............. 080222, ref SDS C3 6T9K
B50497 - ..
B50498 - On 080502 the doctor added Cetuximab and Carboplatin prescribed by
B50499 - UCSF in Chemotherapy Orders, as noted for the meeting with the doctor
B50500 - on 080502, ref SDS 92 NA6F, and citing earlier listings of medications
B50501 - on 080307. UCSF. ref SDS 76 RW3T
B50503 - ..
B50504 - On 080708 Kaiser surgery processing asks for Millie's current
B50505 - medications, per above, ref SDS B0 7Y6F, and cannot access patient
B50506 - medical chart; asks patient to verbally cite 14 medications.
B50508 - ..
B50509 - Kaiser should further add to the medical chart additional medications
B50510 - prescribed by UCSF for weekly treatments...
B50512 - Dexamethasone............... Decadron.. 080313, ref SDS 78 2N43
B50513 - Diphenhydramine............. Benedryl.. 080313, ref SDS 78 NX4N
B50515 - ..
B50516 - Medical Chart continues...
B50518 - 4. Physical Examination
B50520 - Performance Status: 0
B50521 - Lymph nodes: small left supraclavicular LN?
B50522 - Chest wall: erythema increased some on lower left chest wall
B50523 - Ext: LUE edema absent, erythema upper arm stable
B50525 - ..
B50526 - On 080502 the doctor explained that "Performance Status "0" means
B50527 - Millie has evident full mobility and demonstrates no loss of normal
B50528 - functioning. ref SDS 92 NP5M
B50530 - [On 081024 1150 medical chart changes "Performance Status"
B50531 - account to "ECOG Performance Score". ref SDS D2 OP5L
B50533 - ..
B50534 - Small left supraclavicular LN aligns with report at UCSF last week on
B50535 - 080821, ref SDS C2 4C6O, and with rising cancer marker presented in
B50536 - the doctor's medical chart today, per above. ref SDS 0 NN8I
B50538 - ..
B50539 - The doctor said to notify Doctor Rugo immediately to expedite
B50540 - changing treatments, and that he would approve switching to another
B50541 - "targeted" treatment, because Millie's patient profile is now very
B50542 - resistant to chemotherapy.
B50544 - ..
B50545 - Erythema increased some on lower left chest wall may also align with
B50546 - rising cancer marker, CA 15-3 cited in doctor's notes, per above.
B50547 - ref SDS 0 NN8I
B50549 - ..
B50550 - These findings may reverse prior favorable response to treatment on
B50551 - 080627. ref SDS B0 1Z6O
B50553 - [On 080829 2256 Millie's letter to medical team reports
B50554 - that primary care physician at Kaiser palpates lump left
B50555 - supraclavicular, ref SDS C6 RP8T, aligns with findings at
B50556 - UCSF on 080821. ref SDS C2 4C6O
B50558 - ..
B50559 - [On 080918 Brigid's examination at UCSF did not find
B50560 - swelling in left supraclavicular, which may align with the
B50561 - CT test not reporting findings in this area. ref SDS C9
B50562 - N65G
B50564 - ..
B50565 - [On 081016 Brigid and Doctor Rugo palpate lump left
B50566 - supraclavicular, ref SDS D1 J34X; Doctor Rugo orders
B50567 - biopsy. ref SDS D1 J36R
B50569 - ..
B50570 - Medical Chart continues...
B50572 - Lab:
B50573 - CA 15-3 H 141 U/mL
B50575 - BUN 9 mg/dL
B50576 - Chloride H 111 mEq/L
B50577 - CO2 L 20 mEq/L
B50578 - Creatinine 0.39 mg/dL
B50579 - Glucose Random 86 mg/dL
B50580 - Potassium H 5.4 mEq/L
B50581 - Sodium 139 mEq/L
B50582 - Anion Gap 8 mEq/L
B50584 - ..
B50585 - Anticoag Ther? WARFARIN
B50586 - PT, Patient 11.0 Sec
B50588 - ..
B50589 - The doctor lists blood test results from the lab for surgery on
B50590 - 080708. ref SDS B4 075H
B50592 - ..
B50593 - Millie's most recent labs are reported in the record on 080828 getting
B50594 - treatment at UCSF yesterday. ref SDS C5 075H
B50596 - ..
B50597 - Medical Chart continues...
B50599 - 5. Imaging
B50601 - 07/18/08 CT THORAX, ABDOMEN,
B50602 - PELVIS W CONTRAST................... ref SDS B7 0001
B50603 - review of test on 080723............ ref SDS B8 IX4F
B50605 - ..
B50606 - 04/25/08 CT THORAX, ABDOMEN, PELVIS W
B50607 - CONTRAST - no change................ ref SDS 88 9W9I
B50608 - review of test on 080428............ ref SDS 89 DA6Q
B50610 - ..
B50611 - 04/09/08 CHEST, TWO VIEWS.................... ref SDS 85 0H92
B50613 - ..
B50614 - 03/05/08 HUMERUS 2+ VIEWS - normal
B50616 - ..
B50617 - 02/12/08 CT THORAX, ABDOMEN, PELVIS W
B50618 - CONTRAST - increased right
B50619 - axillary LN; infiltrate
B50620 - RML fissure......................... ref SDS 67 FP5H
B50621 - review of test on 080215............ ref SDS 68 EO8F
B50623 - ..
B50624 - 12/27/06 BASE SKULL TO MIDTHIGH
B50625 - PET/CT
B50626 - review of test on 070102............ ref SDS 19 XT4M
B50628 - ..
B50629 - 07/08/06 MRI BRAIN WO/W CONTRAST
B50630 - (STD)- negative
B50631 - review of test on 060711............ ref SDS 12 068M
B50633 - ..
B50634 - Patient history on all image testing is listed in the record on
B50635 - 080723. ref SDS B8 GM3N
B50637 - ..
B50638 - Medical Chart continues...
B50640 - 6. Imp:
B50642 - 1. Metastatic breast cancer (IBC)lung, lymph node and chest
B50643 - wall
B50644 - 2. Recurrent leukopenia
B50645 - 3. Hx of pulmonary embolism
B50646 - 4. Anticoagulation monitoring
B50648 - ..
B50649 - "Leukopenia" is a new term; Millie has a history of "neutropenia," per
B50650 - above. ref SDS 0 NN8I
B50652 - ..
B50653 - Stable nodules in the lungs were cited by the primary care physician
B50654 - at Kaiser in a letter on 070117 to explain the medical chart reporting
B50655 - lung cancer. ref SDS 22 TS8G
B50657 - ..
B50658 - Medical Chart continues...
B50660 - 7. Plan
B50662 - 1. Continue Clinical Trial on Erbitux with weekly Carbo
B50663 - 2. Repeat CT Sept 11, 2008 in Oakland
B50665 - ..
B50666 - On 080903 schedule for CT test at Oakland confirmed. ref SDS C7 025B
B50668 - ..
B50669 - Medical chart continues...
B50671 - 3. Continue Neupogen support as needed
B50673 - 4. Consider different UCSF Clinical Trial if patient
B50674 - progresses vs receiving a single agent here
B50676 - ..
B50677 - The doctor explained today that ending cetuximab treatment at UCSF due
B50678 - to progression of disease, shown by new LN in left supraclavicular and
B50679 - rising cancer marker, per above, ref SDS 0 1Z6O, requires treatment
B50680 - with "trargeted" drugs, because Millie's cancer cells have now mutated
B50681 - through 5 relapses to resist chemotherapy. Earlier on 030606, Doctor
B50682 - Johnson advised that side effects of chemotherapy accumulate to become
B50683 - intolerable, forcing patients to end treatment in order to avoid
B50684 - self-torture, pain and suffering caused by chemotherapy. ref SDS 5
B50685 - ED8H
B50687 - ..
B50688 - [On 100702 1424 Millie received a letter in the mail
B50689 - dated 100624, from Doctor Johnson transmitting Kaiser's
B50690 - lab report for Millie's blood test on 100622. The
B50691 - doctor provides no analysis, nor comment of any kind
B50692 - except "CA 15-3 1116" is circled in ink. ref SDS D0 NC3F
B50694 - ..
B50695 - Today, Doctor Johnson indicated that Millie has been given all of the
B50696 - chemotherapy drugs available at Kaiser for breast cancer, except
B50697 - Gemzar and Navelbine. He feels that since Millie's cancer has mutated
B50698 - to resist chemotherapy, and since prior treatment with numerous
B50699 - chemotherapy agents has accumulated to reduce her body's tolerance for
B50700 - more chemotherapy, Gemzar and Navelbine chemotherapy are no longer
B50701 - appropriate for Millie's patient profile. Millie needs a strategy
B50702 - using newer drugs that "target" cancer cells, and so do not cause pain
B50703 - and suffering from killing healthy cells, like chemotherapy does.
B50705 - ..
B50706 - Doctor Johnson called this strategy treating cancer as a "chronic
B50707 - disease" that extends survival with quality of life. Cetuximab was
B50708 - effective for nearly 2 years, 5-times longer than any other treatment
B50709 - Millie has had in 7 years of treatment for cancer.
B50711 - [On 090213 1140 Millie's treatment history compares
B50712 - cetuximab with 9 or so other treatments. ref SDS D7 AC6G
B50714 - ..
B50715 - [On 090232 1352 case study cancer marker compares
B50716 - duration for Millie's many treatments. ref SDS D9 J13O
B50718 - ..
B50719 - Doctor Johnson asked Millie to notify Doctor Rugo that Kaiser will
B50720 - approve payment for Millie's continued treatment at UCSF with new
B50721 - "targeted" cancer technology, per above. ref SDS 0 PX5V Previously,
B50722 - Doctor Johnson made the original referral to UCSF, because cetuximab
B50723 - targeted cancer cells, and had minimal side effects with no pain and
B50724 - suffering, reported on 070105 1040. ref SDS 20 PK68 Doctor Johnson
B50725 - wants UCSF to submit proposals on providing more "cetuxiab-like"
B50726 - treatments for Millie, so she can switch quickly enough for treatment
B50727 - to be effective, as her cancer continues to mutate.
B50729 - [...in another record today on 080829 2256 Millie's
B50730 - letter to the medical team reports Doctor Johnson's
B50731 - finding of swelled LN in left supraclavicular,
B50732 - ref SDS C6 RP8T, and Millie's progression of disease
B50733 - requires targeted treatments, ref SDS C6 RP9R, wants
B50734 - UCSF to prescribe new treatment in time to be effective.
B50735 - ref SDS C6 RP9R
B50737 - ..
B50738 - [On 081024 1150 Millie met with Doctor Johnson at Kaiser
B50739 - and explained Doctor Rugo reported on 081016 that UCSF
B50740 - has more treatments lined up for future relapses; he
B50741 - wants to get the list so the details do not slip through
B50742 - the cracks. followed up, ref SDS D2 PU4L
B50744 - ..
B50745 - [On 081024 1150 Millie met with Doctor Johnson at
B50746 - Kaiser, ref SDS D2 C45H; examination concurred with UCSF
B50747 - assessment on 081016 finding progression of IBC.
B50748 - ref SDS D2 WK82 The doctor authorized payment for
B50749 - Millie continuing treatment on clinical study at UCSF,
B50750 - ref SDS D2 K67J, and as noted in the Kaiser medical
B50751 - chart, ref SDS D2 OZ5F, explained requirements for
B50752 - treatment to start in time to be effective because
B50753 - Millie's cancer has mutated into a more aggressive
B50754 - disease; the doctor entered into Kaiser's medical chart
B50755 - approval for treatment at UCSF with the sunitinib study.
B50756 - ref SDS D2 OZ5F
B50758 - ..
B50759 - [On 081024 Millie's letter notifies medical team that
B50760 - during meeting at Kaiser with primary care physician the
B50761 - doctor confirmed authorization for Millie's treatment in
B50762 - the sunitinib clinical study, because Millie needs a
B50763 - double agent "targeted" treatment, and Kaiser does not
B50764 - have treatments that can help recover from the 5th
B50765 - relapse of IBC. ref SDS D3 XZ8W
B50767 - ..
B50768 - [On 081219 1140 Doctor Johnson finds favorable response
B50769 - to treatment with sunitinib, ref SDS D4 3L9L; the doctor
B50770 - cites urgency of timely treatment increases when Millie
B50771 - suffers relapse; delay increases risk of losing control
B50772 - for cancer that mutates into more aggressive disease.
B50773 - ref SDS D4 KU6F Doctor Johnson asked Millie to notify
B50774 - Doctor Rugo about planning treatment for the 6th relapse
B50775 - to ensure treatment starts in time to be effective,
B50776 - ref SDS D4 V93O, and asked for a letter from UCSF to
B50777 - facilitate the next referral, ref SDS D4 SU8G; because
B50778 - the 6th relapse will be very serious, ref SDS D4 NS8H;
B50779 - further emphasized need for letter from UCSF
B50780 - recommending treatment on referral from Kaiser.
B50781 - ref SDS D4 E84J
B50783 - ..
B50784 - [On 090123 1326 Doctor Johnson calls and concurs Millie
B50785 - has suffered IBC relapse with cancer marker CA 15-3 303
B50786 - in blood test on 090116 at Kaiser; confirms Millie's
B50787 - cancer has mutated to resist treatments available at
B50788 - Kaiser, authorizes UCSF to prescribe next treatment.
B50789 - ref SDS D5 RK6O
B50791 - ..
B50792 - [On 090204 0219 Millie's letter asks Doctor Rugo to
B50793 - submit proactive planning for follow on treatment after
B50794 - hyperthermia and Doxil for Millie's 6th relapse of IBC.
B50795 - ref SDS D6 278T
B50797 - ..
B50798 - [On 090218 1205 Millie's letter notifies medical team
B50799 - that Doctor Johnson has ordered Millie's continued care
B50800 - at UCSF, citing prior instructions on 080829, 081026,
B50801 - 081219, and on 090123, all authorizing UCSF to begin
B50802 - planning for Millie's next treatment, so that past
B50803 - delays are avoided, because Millie's cancer has mutated
B50804 - through multiple relapses (total of 7 so far) into a
B50805 - very aggressive disease which requires treatment quickly
B50806 - in order to be effective. ref SDS D8 TH6U
B50809 - ..
B50810 - Medical chart continues...
B50812 - 5. RTC 8 weeks
B50815 - ..